COMPANY PROFILE

KEW Group

Comprehensive genomic profiling solutions enhancing oncology precision medicine for better treatment decisions and quality patient care

Cambridge, United StatesFounded 2009Biotech & Life Sciences

Valuation $100–250M Last recorded · 2014

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About KEW Group

KEW, Inc. operates in the healthcare sector, specializing in comprehensive genomic profiling solutions aimed at enhancing precision medicine in oncology. The company serves physicians, molecular labs, and patients by providing detailed genomic information that aids in making informed treatment decisions. KEW's business model involves sequencing tumor samples sent by physicians and delivering clinical reports that highlight potential therapeutic options based on the genetic mutations identified. The company generates revenue through partnerships with healthcare providers and insurance reimbursements, although it is not an in-network provider for all insurance plans. KEW's market includes healthcare providers focused on oncology and precision medicine, as well as patients seeking personalized cancer treatment options. The company collaborates with other healthcare organizations to advance its genomic profiling capabilities and improve cancer care.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2009
Headquarters: Cambridge, United States
Employees: 22
Open positions: None listed
Dealroom signal: 80.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Dec 2014	$17M	$67M	Signet Healthcare Partners · Amzak Capital Management · Arsenal Capital Partners	—
LATE VC✓Equity / VC	Feb 2014	$16M	$64M	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

KEW Group website traffic

Latest recorded traffic for KEW Group is 340 monthly website visits, down 10.5% over the last three months. KEW Group's team grew 0% over the past year.

Latest monthly visits340 3-month web change-10.5% 1-year team growth0%

Monthly website visitsApr 2016–Dec 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
KPKind PharmaceuticalDeveloping small-molecule drugs for anemia and oncology	Hangzhou, China	Operational	—	$55M	$220M
SMSABI MindThe artful mending of mental health and pain through psychedelic-assisted therapies	Calgary, Canada	Operational
NNNantCell \| NantworksDeveloping knowledge by harnessing the power of the immune system to treat cancer	Culver City, United States	Operational
DEDeliniaFounded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases	San Francisco, United States	Acquired
BIBiomXCustomized phage therapies to eradicate harmful bacteria in chronic diseases	Ness Ziona, Israel	Operational
LILantern Pharma, Inc.Lantern develop novel targeted cancer therapeutics	Dallas, United States	Operational
PPPhenex PharmaceuticalsHome – Phenex Pharmaceuticals AG	La Grand-Croix, France	Acquired
PNPneumaCareNon-contact respiratory imaging and assessment technology	Ely, United Kingdom	Operational